

**desmopressin 240 micrograms oral lyophilisate  
(DesmoMelt®) No. (357/07)**

**Ferring Pharmaceuticals Ltd**

## Product Update

9 March 2007

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**desmopressin 240 micrograms oral lyophilisate (DesmoMelt®)** is accepted for use in NHS Scotland for the treatment of primary nocturnal enuresis.

In patients for whom desmopressin oral lyophilisate is an appropriate choice of therapy, it offers a higher dose formulation at an equivalent cost to existing formulations.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

This assessment is based on data submitted by the applicant company up to and including 17 January 2007.

**Chairman,  
Scottish Medicines Consortium**